ERBB2 and breast cancer: Another phase III study, TH3RESA (NCT01419197), compared the effect of trastuzumab emtansine (T-DM1) administration with other treatments of the physician’s choice in patients with HER2+ metastatic BC, showing that T-DM1 reduces the risk of disease progression in patients with BMs at baseline [127].